Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 55-63

  Chiurchiù, Valerio ^a,b   Lanuti, Mirko ^a,b   Catanzaro, Giuseppina ^a,b   Fezza, Filomena ^a,c   Rapino, Cinzia ^b   Maccarrone, Mauro ^a,d  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Atherosclerosis; Cytokines; Endocannabinoid system; Inflammation; Low density lipoproteins

Indexed keywords

ATHEROSCLEROSIS; CYTOKINES; ENDOCANNABINOID SYSTEM; INFLAMMATION; LOW-DENSITY LIPOPROTEINS;

BORNANES; CELL LINE; ENDOCANNABINOIDS; FOAM CELLS; HUMANS; LIPOPROTEINS, LDL; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MACROPHAGES; PYRAZOLES; RECEPTOR, CANNABINOID, CB2; RECEPTORS, SCAVENGER;

EID: 84893865143     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.042     Document Type: Article

References (60)

1. Collot-Teixeira S., Martin J., McDermott-Roe C., Poston R., McGregor J.L. CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007, 75:468-477.
2. Greaves D.R., Gordon S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. JLipid Res 2009, 50:282-286.
3. Ross R. Atherosclerosis: an inflammatory disease. NEngl J Med 1999, 340:115-126.
4. Wick G., Knoflach M., Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004, 22:361-403.
5. Chiurchiù V., Maccarrone M. Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2011, 15:2605-2641.
6. Beltowski J., Wojcicka G., Jamroz-Wisniewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf 2009, 4:209-228.
7. Centonze D., Finazzi-Agrò A., Bernardi G., Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Curr Pharm Des 2008, 14. 2370-2342.
8. Mallat A., Teixeira-Clerc F., Deveaux V., Manin S., Lotersztajn S. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol 2011, 163:1432-1440.
9. Steffens S., Veillard N.R., Arnaud C., et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005, 434:782-786.
10. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 2005, 6:672-679.
11. Di Marzo V., Bisogno T., De Petrocellis L. Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol 2007, 14:741-756.
12. Di Marzo V., De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 2010, 17:1430-1449.
13. Jiang L.S., Pu J., Han Z.H., Hu L.H., He B. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res 2009, 81:805-813.
14. Dol-Gleizes F., Paumelle R., Visentin V., et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2009, 29:12-18.
15. Mach F., Steffen S. The role of endocannabinoid system in atherosclerosis. JNeuroendocrinol 2008, 20:53-57.
16. Rajesh M., Mukhopadhyay P., Hasko G., Liaudet L., Mackie K., Pacher P. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol 2010, 210:688-700.
17. Pacher P. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?. Arterioscler Thromb Vasc Biol 2009, 29:7-9.
18. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. NEngl J Med 2005, 353:2121-2134.
19. Mach F., Montecucco F., Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 2008, 153:290-298.
20. Braunersreuther V., Mach F. Leukocyte recruitment in atherosclerosis: potential targets for therapeutic approaches?. Cell Mol Life Sci 2006, 63:2079-2088.
21. Chiurchiù V., Izzi V., D'Aquilio F., Carotenuto F., Di Nardo P., Baldini P.M. Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept 2008, 148:26-32.
22. Izzi V., Chiurchiù V., D'Aquilio F., et al. Endomorphin-1 inhibits the activation and the development of a hyporesponsive-like phenotype in lipopolysaccharide- stimulated THP-1 monocytes. Int J Immunopathol Pharmacol 2008, 21:833-843.
23. Izzi V., Chiurchiù V., D'Aquilio F., et al. Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. Int J Oncol 2009, 34:543-550.
24. Chiurchiù V., Izzi V., D'Aquilio F., et al. Endomorphin-1 prevents lipid accumulation via CD36 down-regulation and modulates cytokines release from human lipid-laden macrophages. Peptides 2011, 32:80-85.
25. Chiurchiù V., Cencioni M.T., Bisicchia E., et al. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann Neurol 2013, 73:626-636.
26. Pasquariello N., Catanzaro G., Marzano V., et al. Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. JBiol Chem 2009, 284:29413-29426.
27. Cencioni M.T., Chiurchiù V., Catanzaro G., et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 2010, 5:e8688.
28. Gattinoni S., De Simone C., Dallavalle S., et al. Enolcarbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system. Chem Med Chem 2010, 1(5):357-360.
29. Fezza F., Gasperi V., Mazzei C., Maccarrone M. Radiochromatographic assay of N-acyl-phosphatidylethanolamine-specific phospholipase D activity. Anal Biochem 2005, 339:113-120.
30. Bisogno T., Howell F., Williams G., et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. JCell Biol 2003, 163:463-468.
31. Gasperi V., Fezza F., Pasquariello N., et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 2007, 64:219-229.
32. Oddi S., Dainese E., Sandiford S., et al. Effects of palmitoylation of Cys(415) in helix 8 of the CB(1) cannabinoid receptor on membrane localization and signalling. Br J Pharmacol 2012, 165:2635-2651.
33. Pucci M., Pasquariello N., Battista N., et al. Endocannabinoids stimulate human melanogenesisvia type-1 cannabinoidreceptor. JBiol Chem 2012, 287:15466-15478.
34. Bari M., Tedesco M., Battista N., et al. Characterization of the endocannabinoid system in mouse embryonic stem cells. Stem Cells Dev 2011, 20:139-147.
35. Thomas B.F., Gilliam A.F., Burch D.F., Roche M.J., Seltzman H.H. Comparative receptor binding analyses of cannabinoid agonists and antagonists. JPharmacol Exp Ther 1998, 285:285-292.
36. Chuang H.H., Prescott E.D., Kong H., et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001, 411:957-962.
37. Netherland Courtney D., Pickle Theresa G., Bales Alicia, Thewke Douglas P. Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemicLdlr-null mice. Atherosclerosis 2010, 213:102-108.
38. Hoyer F.F., Steinmetz M., Zimmer S., et al. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells invivo. JMol Cell Cardiol 2011, 51:1007-1014.
39. Basu S., Dittel B.N. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 2011, 51:26-38.
40. Pacher P., Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system?. Prog Lipid Res 2011, 50:193-211.
41. Hao M.X., Jiang L.S., Fang N.Y., et al. The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages. JLipid Res 2010, 51:2181-2190.
42. Di Filippo C., Rossi F., Rossi S., D'Amico M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. JLeukoc Biol 2004, 75:453-459.
43. Montecucco F., Lenglet S., Braunersreuther V., et al. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. JMol Cell Cardiol 2009, 46:612-620.
44. Wung B.S., Ni C.W., Wang D.L. ICAM-1 induction by TNFalpha and IL-6 is mediated by distinct pathways via Rac in endothelial cells. JBiomed Sci 2005, 12:91-101.
45. Javaid K., Rahman A., Anwar K.N., Frey R.S., Minshall R.D., Malik A.B. Tumor necrosis factor-alpha induces early-onset endothelial adhesivity by protein kinase Czeta-dependent activation of intercellular adhesion molecule-1. Circ Res 2003, 92:1089-1097.
46. Brånén L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004, 24:2137-2142.
47. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
48. Davenport P., Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003, 163:1117-1125.
49. Hauer A.D., Uyttenhove C., de Vos P., et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 2005, 112:1054-1062.
50. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
51. Oberholzer A., Oberholzer C., Moldawer L.L. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002, 30:S58-S63.
52. Carson W.E., Lindemann M.J., Baiocchi R., et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995, 85:3577-3585.
53. Gimeno M.J., Pascual G., García-Honduvilla N., et al. Modulatory role of IL10 in endothelial cell damage and platelet adhesion. Histol Histopathol 2003, 18:695-702.
54. Halvorsen B., Waehre T., Scholz H., et al. Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. JLipid Res 2005, 46:211-219.
55. Han X., Kitamoto S., Lian Q., Boisvert W.A. Interleukin-10 facilitates bothcholesterol uptake and efflux in macrophages. JBiol Chem 2009, 284:32950-32958.
56. Steffens S., Pacher P. Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol 2012, 167:313-323.
57. Liu Y.J., Fan H.B., Jin Y., et al. Cannabinoid receptor 2 suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5 pathway. JBiol Chem 2013, 288:13551-13562.
58. Ramirez S.H., Haskó J., Skuba A., et al. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. JNeurosci 2012, 32:4004-4016.
59. Rajesh M., Mukhopadhyay P., Haskó G., Huffman J.W., Mackie K., Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 2008, 153:347-357.
60. Rajesh M., Mukhopadhyay P., Batkai S., et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007, 293:H2210-H2218.